IDEAYA’s IDE161 Receives Fast Track Designation for HR+ Her2- Breast Cancer
The FDA has granted IDEAYA Biosciences fast track status for IDE161 as a treatment for HR+, Her2- breast cancer. The therapy is a selective inhibitor of ADP ribose glycohydrolase…